Margo B. Minissian

Margo B. Minissian

Auto-generated profile, based on publicly available information

Margo B. Minissian

Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in Circulation
Verified
Journal Article
Closed access
PDF file
MMMargo B. Minissian
Margo B. Minissian
SKSarah Kilpatrick
Sarah Kilpatrick
JEJo-Ann Eastwood
Jo-Ann Eastwood
WRWendie A. Robbins
Wendie A. Robbins
EAEynav E. Accortt
Eynav E. Accortt
C. Noel Bairey MerzC. Noel Bairey Merz
C. Noel Bairey Merz
Cardiovascular disease (CVD) risk factors are well established. However, little is known about a woman’s cardiovascular response to pregnancy, which appears to be an early marker of future maternal CVD risk. Spontaneous preterm delivery (sPTD) has been associated with a ≤3-fold increased risk of maternal CVD death later in life compared with having a term delivery. This review focuses on 3 key areas to critically assess the association of sPTD and future maternal CVD risk: (1) CVD risk factors, (2) inflammatory biomarkers of interest, and (3) specific forms of vascular dysfunction, such as endothelial function and arterial stiffness, and mechanisms by which each may be linked to sPTD. The association of sPTD with subsequent future maternal CVD risk suggests that a woman’s abnormal response to pregnancy may serve as her first physiological stress test. These findings suggest that future research is needed to understand why women with sPTD may be at risk for CVD to implement effective interventions earlier in a woman’s life.

29 August 2022 in JACC
Verified
Journal Article
Closed access
MMMargo B. Minissian
Margo B. Minissian
PMPuja K. Mehta
Puja K. Mehta
SHSharonne N. Hayes
Sharonne N. Hayes
KPKi Park
Ki Park
JWJanet Wei
Janet Wei
CPCarl J. Pepine
Carl J. Pepine

20 December 2017 in JMIR Research Protocols
Verified
Journal Article
Open access
KBKade Birkeland
Kade Birkeland
RKRaj M Khandwalla
Raj M Khandwalla
IKIlan Kedan
Ilan Kedan
CSChrisandra Shufelt
Chrisandra Shufelt
PMPuja Mehta
Puja Mehta
C. Noel Bairey MerzC. Noel Bairey Merz
C. Noel Bairey Merz
Digital wearable devices provide a "real-world" assessment of physical activity and quantify intervention-related changes in clinical trials. However, the value of digital wearable device-recorded physical activity as a clinical trial outcome is unknown. Because late sodium channel inhibition (ranolazine) improves stress laboratory exercise duration among angina patients, we proposed that this benefit could be quantified and translated during daily life by measuring digital wearable device-determined step count in a clinical trial. We conducted a substudy in a randomized, double-blinded, placebo-controlled, crossover trial of participants with angina and coronary microvascular dysfunction (CMD) with no obstructive coronary artery disease to evaluate the value of digital wearable device monitoring. Ranolazine or placebo were administered (500-1000 mg twice a day) for 2 weeks with a subsequent 2-week washout followed by crossover to ranolazine or placebo (500-1000 mg twice a day) for an additional 2 weeks. The outcome of interest was within-subject difference in Fitbit Flex daily step count during week 2 of ranolazine versus placebo during each treatment period. Secondary outcomes included within-subject differences in angina, quality of life, myocardial perfusion reserve, and diastolic function. A total of 43 participants were enrolled in the substudy and 30 successfully completed the substudy for analysis. Overall, late sodium channel inhibition reduced within-subject daily step count versus placebo (mean 5757 [SD 3076] vs mean 6593 [SD 339], P=.01) but did not improve angina (Seattle Angina Questionnaire-7 [SAQ-7]) (P=.83). Among the subgroup with improved angina (SAQ-7), a direct correlation with increased step count (r=.42, P=.02) was observed. We report one of the first studies to use digital wearable device-determined step count as an outcome variable in a placebo-controlled crossover trial of late sodium channel inhibition in participants with CMD. Our substudy demonstrates that late sodium channel inhibition was associated with a decreased step count overall, although the subgroup with angina improvement had a step count increase. Our findings suggest digital wearable device technology may provide new insights in clinical trial research. Clinicaltrials.gov NCT01342029; https://clinicaltrials.gov/ct2/show/NCT01342029 (Archived by WebCite at http://www.webcitation.org/6uyd6B2PO).

1 April 2021 in Nurse Leader
Verified
Journal Article
Open access
MMMargo B. Minissian
Margo B. Minissian
JBJennifer Ballard-Hernandez
Jennifer Ballard-Hernandez
BCBernice Coleman
Bernice Coleman
JCJose Chavez
Jose Chavez
LSLorraine Sheffield
Lorraine Sheffield
DMDavid Marshall
David Marshall
A multispecialty nursing team plays a crucial role in key decision making, education, prevention, screening, assessment, diagnosis, management, data collection and dissemination of best practices during the novel coronavirus disease (COVID-19) pandemic. Using examples from a large, tertiary medical center in Los Angeles, this paper highlights contributions made by multispecialty nursing specialties to optimize health and safety for patients and frontline health care workers. Recognizing nurses’ ongoing critical role encourages and informs further collaboration and serves as a catalyst to innovation for a healthier tomorrow. The result of the COVID-19 pandemic will be felt for years to come.

20 October 2021 in Preventive Medicine
Verified
Journal Article
Open access
JEJoseph E. Ebinger
Joseph E. Ebinger
RLRoy Lan
Roy Lan
NSNancy Sun
Nancy Sun
MWMin Wu
Min Wu
Sandy JoungSandy Joung
Sandy Joung
MMMargo B. Minissian
Margo B. Minissian
Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P < 0.001), with >80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19–2.51) and dose 2 (1.76, 1.28–2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last <2 days. Appreciable post-vaccine symptoms are associated with female sex, prior COVID-19, younger age, and hypertension. This information can aid clinicians in advising patients on the safety and expected symptomatology associated with vaccination.

1 January 2021 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
MMMohamed Osama Mohamed
Mohamed Osama Mohamed
TCTahmeed Contractor
Tahmeed Contractor
DZDonah Zachariah
Donah Zachariah
HSHarriette G.C. van Spall
Harriette G.C. van Spall
PPPurvi Parwani
Purvi Parwani
MMMamas A. Mamas
Mamas A. Mamas